Safety of Inactivated SARS-CoV-2 Vaccines Among Adults with Experience of Allergies to Food or Medicines

Figures & data

Table 1 Baseline Characteristics of the Participants

Variable	Total, N=150	FA, N=50	DA, N=91
Age (year), mean (SD)	33.9(9.7)	33.0(9.7)	33.84(9.65)
Sex, n (%)
Male	30(20)	14(28)	15(16.5)
Female	120(80)	36(72)	76(83.5)
Comorbidities, n (%)
Allergic disease	67(44.7)	24(48)	36(39.6)
Hypertension	6(4)	2(4)	4(4.4)
Diabetes	1(0.7)	0(0)	1(1.1)
Thyroid disease	3(2)	2(4)	1(1.1)
Chronic gastritis	5(3.3)	3(6)	2(2.2)
Anaemia	1(0.7)	0(0)	1(1.1)
Allergic disease, n (%)
Asthma	4(2.7)	0(0)	1(1.1)
Allergic rhinitis	41(27.3)	12(24)	24(26.4)
Atopic dermatitis	31(20.7)	14(28)	14(15.4)
Food Allergy, n (%)	59(39.3)
Seafood	21(14)	18(36)
Fruits	23(15.3)	18(36)
Red meat	2(1.3)	2(4)
Egg	1(0.7)	1(2)
Milk	3(2)	2(4)
Alcohol	4(2.7)	4(8)
Peanut	1(0.7)	1(2)
Others	8(5.3)	7(14)
Drug Allergy, n (%)	100(66.7)
Antibiotic allergy	96(64)		87(95.6)
Penicillin	70(46.7)		64(70.3)
Cephalosporin	22(14.7)		19(20.9)
Sulfonamide	4(2.7)		4(4.4)
Fluoroquinolone	6(4)		6(6.6)
Macrolide	1(0.7)		1(1.1)
Aminoglycosides	1(0.7)		0(0)
Chloramphenicol	2(1.3)		2(2.2)
Clindamycin	1(0.7)		1(1.1)
Fosfomycin	1(0.7)		1(1.1)
Vaccines^a	4(2.7)		4(4.4)
Others	3(2)		3(3.3)

Note: ^aTetanus vaccine/influenza vaccine.

Abbreviations: FA, food allergy; DA, drug allergy.

Table 2 Adverse Reactions Following Vaccination in Patients with Food and/or Drug Allergies

n (%)	After First Dose			After Second Dose^a
	Total, N=150	FA, N=50	DA, N=91	Total, N=147	FA, N=50	DA, N=89
No symptoms	66(44)	27(54)	38(42)	86(58.5)	33(66)	51(57.3)
Local reactions	47(31.3)	12(24)	28(30.8)	33(22.4)	7(14)	21(23.6)
Pain	45(30)	11(22)	27(29.7)	33(22.4)	6(12)	21(23.6)
Grade 1	36(24)	7(14)	25(27.5)	30(20.4)	6(12)	20(22.5)
Grade 2	9(6)	4(8)	2(2.2)	3(2)	0(0)	1(1.1)
Redness	2(1.3)	1(2)	0(0)	2(1.4)	1(2)	0(0)
Grade 1	2(1.3)	1(2)	0(0)	2(1.4)	1(2)	0(0)
Swelling	3(2)	0(0)	2(2.2)	4(2.7)	1(2)	2(2.2)
Grade 1	2(1.3)	0(0)	1(1.1)	4(2.7)	1(2)	2(2.2)
Grade 2	1(0.7)	0(0)	1(1.1)	0(0)	0(0)	0(0)
Pruritus	1(0.7)	1(2)	0(0)	0(0)	0(0)	0(0)
Grade 1	1(0.7)	1(2)	0(0)	0(0)	0(0)	0(0)
Systemic reactions	52(34.7)	15(30)	32(35.2)	37(25.2)	12(24)	22(24.7)
Vomiting/Nausea	4(2.7)	1(2)	3(3.3)	1(0.7)	1(2)	0(0)
Grade 1	4(2.7)	1(2)	3(3.3)	1(0.7)	1(2)	0(0)
Diarrhea	9(6)	4(8)	3(3.3)	2(1.4)	1(2)	1(1.1)
Grade 1	7(4.7)	3(6)	2(2.2)	2(1.4)	1(2)	1(1.1)
Grade 2	1(0.7)	1(2)	0(0)	0(0)	0(0)	0(0)
Grade 3	1(0.7)	0(0)	1(1.1)	0(0)	0(0)	0(0)
Skin rash	7(4.7)	2(4)	5(5.5)	3(2)	2(4)	1(1.1)
Grade 1	5(3.3)	1(2)	4(4.4)	1(0.7)	1(2)	0(0)
Grade 2	2(1.7)	1(2)	0(0)	2(1.4)	1(2)	1(1.1)
Headache	6(4)	1(2)	5(5.5)	5(3.4)	3(6)	2(2.2)
Grade 1	5(3.3)	1(2)	4(4.4)	5(3.4)	3(6)	2(2.2)
Grade 2	1(0.7)	0(0)	1(1.1)	0(0)	0(0)	0(0)
Vertigo	11(7.3)	4(8)	6(6.6)	9(6.1)	4(8)	5(5.6)
Grade 1	8(5.3)	3(6)	4(4.4)	8(5.4)	4(8)	4(4.5)
Grade 2	3(2)	1(2)	2(2.2)	1(0.7)	0(0)	1(1.1)
Fatigue	24(16)	7(14)	13(14.3)	20(13.6)	6(12)	12(13.5)
Grade 1	22(14.7)	6(12)	12(13.2)	19(12.9)	6(12)	11(12.4)
Grade 2	3(1.3)	1(2)	1(1.1)	1(0.7)	0(0)	1(1.1)
Chills	3(2)	0(0)	2(2.2)	0(0)	0(0)	0(0)
Grade 1	3(2)	0(0)	2(2.2)	0(0)	0(0)	0(0)
Sore throat	9(6)	5(10)	4(4.4)	7(4.8)	3(6)	4(4.5)
Grade 1	6(4)	4(8)	2(2.2)	7(4.8)	3(6)	4(4.5)
Grade 2	1(0.7)	0(0)	1(1.1)	0(0)	0(0)	0(0)
Grade 3	2(1.3)	1(2)	1(1.1)	0(0)	0(0)	0(0)
Cough	8(5.3)	3(6)	5(5.5)	6(4.1)	3(6)	3(3.4)
Grade 1	5(3.3)	2(4)	3(3.3)	5(3.4)	3(6)	2(2.2)
Grade 2	2(1.3)	0(0)	2(2.2)	1(0.7)	0(0)	1(1.1)
Grade 3	1(0.7)	1(2)	0(0)	0(0)	0(0)	0(0)
Chest tightness	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Palpitation of heart	0(0)	0(0)	0(0)	1(0.7)	0(0)	1(1.1)
Grade 1	0(0)	0(0)	0(0)	1(0.7)	0(0)	1(1.1)
New or worsened muscle pain	7(4.7)	4(8)	3(3.3)	4(2.7)	1(2)	2(2.2)
Grade 1	6(4)	3(6)	3(3.3)	4(2.7)	1(2)	2(2.2)
Grade 2	1(0.7)	1(2)	0(0)	0(0)	0(0)	0(0)
New or worsened joint pain	1(0.7)	0(0)	1(1.1)	1(0.7)	1(2)	0(0)
Grade 1	1(0.7)	0(0)	1(1.1)	1(0.7)	1(2)	0(0)
Fever	4(2.7)	3(6)	1(1.1)	3(2)	2(4)	1(1.1)
Grade 1	2(1.3)	2(4)	0(0)	1(1.4)	2(4)	0(0)
Grade 2	2(1.3)	1(2)	0(0)	1(0.7)	0(0)	1(1.1)
Somnolence	2(1.3)	1(2)	1(1.1)	0(0)	0(0)	0(0)
Grade 1	2(1.3)	1(2)	1(1.1)	0(0)	0(0)	0(0)
Stuffy nose	3(2)	0(0)	3(3.3)	2(1.4)	0(0)	2(2.2)
Grade 1	2(1.3)	0(0)	2(2.2)	1(0.7)	0(0)	1(1.1)
Grade 2	1(0.7)	0(0)	1(1.1)	1(0.7)	0(0)	1(1.1)
Abdominal pain	1(0.7)	1(2)	0(0)	0(0)	0(0)	0(0)
Grade 1	1(0.7)	1(2)	0(0)	0(0)	0(0)	0(0)
Chest pain	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Lymphadenopathy	1(0.7)	0(0)	0(0)	0(0)	0(0)	0(0)
Grade 1	1(0.7)	0(0)	0(0)	0(0)	0(0)	0(0)

Notes: The data are presented as n (%). ^aAfter first vaccination, follow-up was carried out, finally 3 participants (one from “Food Allergy” and two from “Drug Allergy” subgroup) declined to receive the second dose of inactivated vaccine.

Abbreviations: FA, food allergy; DA, drug allergy.

Figure 1 Local and systemic reactions after receiving the inactivated COVID-19 vaccine in the participants with food and/or drug allergies.

Figure 2 Local and systemic reactions after receiving the inactivated COVID-19 vaccine in the participants with food allergy.

Figure 3 Local and systemic reactions after receiving the inactivated COVID-19 vaccine in the participants with drug allergy.